Roivant Sciences Ltd (FRA:87S)
€ 11.525 0.15 (1.32%) Market Cap: 8.62 Bil Enterprise Value: 3.56 Bil PE Ratio: 2.21 PB Ratio: 1.78 GF Score: 60/100

Roivant Sciences Ltd at Goldman Sachs Global Healthcare Conference Transcript

Jun 14, 2022 / 03:40PM GMT
Release Date Price: €3.22 (-8.66%)
Corinne Jenkins
Goldman Sachs Group, Inc., Research Division - Research Analyst

Thanks for joining us here at the 43rd Annual Goldman Sachs Global Healthcare Conference. This morning, I'm pleased to welcome the team from Roivant Sciences. We've got Richard Pulik, the Chief Financial Officer; and Mayukh Sukhatme, the Chief Investment Officer at Roivant. So thanks guys for joining us.

Questions & Answers

Corinne Jenkins
Goldman Sachs Group, Inc., Research Division - Research Analyst

And maybe just to start, can you provide a brief overview of the company, including some of the key subsidiaries and how that all fits together under this Roivant umbrella?

Mayukh Sukhatme
Roivant Sciences Ltd. - President & CIO

Sure. So I'll start and then turn it over to Richard too to add. So we're a company that went public last year. We're roughly a -- I think, these days a $2.5 billion or $2.6 billion market cap company, about $2.1 billion in cash, another $300 million in public banks and another $700 million stake

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot